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Abstract
Palliative care emphasizes an interdisciplinary approach to care to improve quality of life and relieve symptoms.
Palliative care is provided in many ways; in hospices, hospital units, and the community. However, the greatest
proportion of palliative care is in the community. In hospice and palliative care units in hospitals, clinical phar-
macists are part of the interdisciplinary team and work closely with other health care professionals. Their expertise
in the therapeutic use of medications is highly regarded, particularly as many palliative care patients have complex
medication regimens, involving off-label or off-license prescribing that increases their risk for drug-related prob-
lems. However, this active involvement in the palliative care team is not reflected in the community setting, despite
the community pharmacist being one of the most accessible professionals in the community, and visiting a com-
munity pharmacist is convenient formost people, even those who have limited access to private or public transport.
Thismay be due to a general lack of understanding of skills and knowledge that particular health professionals bring
to the interdisciplinary team, a lack of rigorous research supporting the necessity for the community pharmacist’s
involvement in the team, or it could be due to professional tensions. If these barriers can be overcome, community
pharmacists are well positioned to become active members of the community palliative care interdisciplinary team
and respond to the palliative care needs of patients with whom they often have a primary relationship.
The interdisciplinary team approach is central to thephilosophy and practice of palliative care.1,2 In hospice
and palliative care units in hospitals clinical pharmacists are
part of this interdisciplinary team and work closely with
other health care professionals to provide pharmaceutical
care to detect, prevent, and resolve medication-related
problems.3–5 Clinical pharmacists in these settings routinely
undertake patient assessments, systematic medication re-
views, patient counselling at discharge and follow-up, home
visits, and participate in palliative care clinics.4,6 Their ex-
pertise in the therapeutic use of medications is important to
patient care, particularly as many palliative care patients
have complex medication regimens, often involving off-label
or off-license prescribing that increases their risk for
medication-related problems.7 However, this involvement
in the palliative care team does not occur in the community
and community pharmacists are not perceived as active or
valued members of community-based palliative health care
teams.8 Interestingly, Gilbar and Stefaniuk4 highlight that
the Oxford Textbook of Palliative Medicine9 has only three
sentences related to pharmacists in its chapter on the palli-
ative care interdisciplinary team. This limited information
describes the pharmacist as a resource and support for the
physician rather than an independent contributor to the
team.
Certainly, community pharmacists are an underutilized
resource in community-based palliative care. This may be due
to a general lack of understanding of skills and knowledge
that particular health professionals bring to the interdisci-
plinary team,10 a lack of rigorous research supporting the
necessity for the community pharmacist’s involvement in the
team,4 or it could be due to professional tensions. Gilbert11
describes this tension and competition between the medical
profession and pharmacists in South Africa as physicians
protecting their right to make decisions about their patients’
medications. Further support for professional tension is of-
fered by Montgomery et al.12 who report that a major barrier
in the implementation of a pharmaceutical care service in the
United Kingdom was the difficulty of involving doctors in
referring patients.
1WA Centre for Cancer and Palliative Care and Curtin Health Innovation Research Institute, 4School of Pharmacy and Curtin Health
Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.
2School of Nursing, Midwifery and Postgraduate Medicine, Edith Cowan University, Perth, Western Australia, Australia.
3Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia.
5School of Population Health, University of Western Australia, Crawley, Western Australia, Australia.
JOURNAL OF PALLIATIVE MEDICINE
Volume 14, Number 1, 2011
ª Mary Ann Liebert, Inc.
DOI: 10.1089/jpm.2010.0369
7
The Pharmacy Guild of Australia (the Guild) has initiated
steps to enhance the role of community pharmacists in palli-
ative care in Australia in order to improve the medication
management of palliative care patients and patient outcomes.
Although not forming the basis of their substantive work,
community pharmacists are well-suited to respond to the
palliative care needs of clients, especially as they often have a
primary relationship with families. With extra training com-
munity pharmacists could, potentially, take on a patient-
centerd role; contribute to palliative care patients’ self-care
with regard to prescriptionmedications, and over-the-counter
medicines; provide prescribing advice to general practitioners
(GPs); and facilitate continuity of patient care between health
care settings.7 Further roles could include improving adher-
ence to prescribed drug regimens, minimizing adverse drug
interactions (adverse events), and providing support to the
patient and family over the course of the illness.8,13 The
community pharmacist, therefore, is well-positioned to be an
active member of the community palliative care interdisci-
plinary team.
Context
In Australia, palliative care services are provided in desig-
nated palliative care units such as hospices, in dedicated and
nondedicated palliative care beds in acute hospitals, and in the
community14,15 where palliative care patients receive care in
their own home or other community living facilities such as
aged care facilities.16 This reflects the shift in health care pro-
vision from hospital-based care to ‘‘hospital in the home,’’17
which has been supported by family and community primary
health care professionals for some time in Australia18 and
underpins the impetus for the Guild’s initiative to increase the
role of the community pharmacist in palliative care. Patients in
the community may move in and out of other settings at dif-
ferent times during the course of their illness but the majority
of care is in the community. Ninety percent of patient care in
the final year of life occurs at home,19 with many people
moving to an inpatient setting only in the final days of their
life. Ill children, in particular, prefer to remain at home
whenever possible, and parents need ongoing interdisciplin-
ary support throughout their child’s illness trajectory.20,21
Dying at home has been identified as the preferred care
option for approximately 58% of people21 but less than a third
of adults actually die at home.23,24 Predictors for home death
in palliative care patients is associated with the availability of
one or more carers, the patient’s and carer’s desire for death at
home and, importantly for the argument presented in this
paper, the availability of skilled primary care support in the
community.25–27
Certainly, providing in-home care for people at the end of
life offers a number of benefits, most importantly maintaining
quality of life and a sense of control over one’s illness.28
Community care can also offer significant economic benefits,
with economic modelling suggesting that end-of-life care
provided in a home setting is a cost-effective method of ser-
vice delivery.29 However, community care delivery has be-
come increasingly complex, with more patients receiving
comprehensive care in the home setting. As a result, much of
the burden of caring is managed in the community, with the
greatest burden falling to primary caregivers to provide care
that may be complex and time consuming.30,31
An additional contextual factor is the strong impetus for
palliative care to be instigated at the time of diagnosis of a life-
threatening illness32 and to continue over the course of the
illness.33 Thus, researchers and practitioners are considering
approaches other than the medical model of care, which is
focused on the terminal stage of illness. For instance, Salau,
Rumbold, and Young34 draw upon public health approaches
and recommend a palliative care approach that builds the
capacity of local communities in supporting people living
with chronic illness nearing end of life. Given that community
pharmacies are recognized as stable delivery points for health
care services in their local communities, such an approach
would provide an ideal context for community pharmacists to
contribute to community-based palliative care.
In Australia the provision of care in the community is
complicated by two key factors. First, the capacity of GPs to
provide care is already stretched; there is an insufficient num-
ber of GPs, particularly in rural and remote areas, and GPs are
working fewer hours. GPs are also caring for an increasing
number of patients with chronic diseases (often multiple mor-
bidities) with complex care needs.35 Second, a declining death
rate and increasing life expectancy for both sexes36 contribute to
an aging population, which is increasingly characterized by
multimorbidity.14,37 Twelve-and-a-half percent of people were
aged over sixty-five years in 2001 and it is estimated that this
will rise to 25% by 2052.38 Inevitably, the number of people
with chronic and/or life-threatening diseases will increase and,
as a result, so will the number of patients requiring palliative
care. The resulting demand on primary care will be marked,
giving further support to enhancing the role of the community
pharmacist in palliative care.
The Pharmacist in Primary Care
Visiting a pharmacist is convenient for most people, even
those who have limited access to private or public transport39
and around 90% of the population sees a pharmacist at least
once every year.40,41 Community pharmacists are also easier
to access than other primary care providers, especially after
many GPs’ surgeries close42 and it is not usually necessary to
make an appointment to obtain medication or advice. As
such, the community pharmacist is likely to encounter palli-
ative care patients and their carers and to be providing
medication to patients receiving home-based palliative care.42
Hence, community pharmacists are well-positioned to pro-
vide locally based primary care services.
A number of potential roles for the pharmacist in the gen-
eral primary care arena have been developed and evaluated
(including involvement in managing chronic conditions).43,44
This expansion of the community pharmacist’s role has been a
focus of interest internationally since the 1990s when an edi-
torial in the British Medical Journal outlined the advantages of
greater integration of community pharmacists into the pri-
mary health care team. Research findings strongly suggest
that pharmacists’ health knowledge is underused.41 In re-
sponse, the Department of Health (DoH)45 in the United
Kingdom introduced a program for pharmaceutical public
health. This DoH report highlights the pharmacist’s role in
supporting people with long-term chronic and acute health
conditions. The pharmacist’s potential contribution includes
providing information regarding the effective use of medi-
cines and medication management, support for self-managed
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care, and disease specific care management information and
strategies. The report emphasizes working in partnership
with other health care professionals and community leaders
and the necessity for community pharmacists to be part of
interdisciplinary care teams.
The Australian Government Department of Health and
Ageing (DoHA) and theGuild recognize that with training and
support community pharmacists can have an expanded role
in helping patients self-manage chronic conditions and/or
improve their medication use. Since 2000, the Guild and the
DoHA have initiated pilot programs to determine the feasi-
bility of rolling out targeted pharmacy disease management
services in community pharmacies across Australia.46,47 These
services are intended to complement management by the pa-
tient’s GP and other health care professionals. However, we
must bemindful that, despite the successful involvement of the
community pharmacist in the primary care team, palliative
care is a specialized field and there are additional barriers to be
overcome to enable community pharmacists to become ac-
tively involved in the palliative care area.
Barriers to Community Pharmacists Playing a Role
in the Palliative Care Interdisciplinary Team
Community pharmacists wanting to provide targeted
pharmaceutical care for palliative care patients face several
barriers. A remuneration-based supply service does not
favor the delivery of relatively time-intensive pharmaceutical
care.48–50 Moreover, in Australia, community pharmacists are
not among the allied health professionals eligible to join an
interdisciplinary team in providing services to patients with
chronic conditions and complex care needs on referral from
their GP. Patient care is managed and reimbursed under an
Enhanced Primary Care (EPC) plan, a GP Management Plan,
and Team Care Arrangements.51,52 As such, tension between
the business side of community pharmacies and a public
health model is likely if community pharmacists cannot de-
rive adequate financial remuneration for providing palliative
care-related services (fee-for-service that depends upon pa-
tients’ willingness to pay) or reimbursement (with broader
eligibility criteria and a viable payment structure).
Community pharmacists will also require continuing pro-
fessional education (CPE) if they are to provide pharmaceu-
tical care for palliative care patients confidently.13 It is not
uncommon to find that community pharmacists dispensing
medications for patients of home-based palliative care
programs are unfamiliar with nonformulary or uncommon
palliative care medications.53 Additionally, pharmacists’
misconceptions about opiate use in patient populations re-
ported in the literature have implications for community-
based palliative care. For example, Joranson and Gilson54
found that Wisconsin pharmacists’ views on addiction, drug
abuse, and diversion interfered with their dispensing of valid
prescriptions for opioid pain medications to patients with
chronic cancer and those with noncancer pain, with or with-
out history of opioid abuse, in long-term care facilities, hos-
pitals, and outpatient clinics. This restricted patients’ access to
pain relief medicines and jeopardized their painmanagement.
Community pharmacists from urban and rural communities
in a small study in Australia reported that they deliver palli-
ative cancer care services only infrequently and consequently
lacked knowledge in this area.40 The five palliative care topics
respondents most wanted to learn about in an educational
program were: management of cancer pain; management of
nonpain symptoms or side effects; drug interactions with
palliative cancer treatments; risk factors, presentation, treat-
ments, and prognosis of common cancers; and the principles
of palliative care. A study conducted in Japan found that
community pharmacists prioritized a need for skills to com-
municate effectively with patients and carers.8
An enhanced role in palliative care requires that commu-
nity pharmacists have the capacity to provide equipment,
including drug administration equipment, and that they stock
(or have access to) the full range of palliative care pharma-
ceuticals.53 However, retail pharmacists and home care nurses
surveyed in Dublin, Ireland, reported that the main problem
causing delays for newly referred home care patients was
obtaining palliative care drugs, particularly unlicensed
drugs.55 This finding was mirrored in Japan.8
Finally, the available research evidence on community
pharmacy involvement in primary care generally is inconclu-
sive. Pharmaceutical care interventions may be ineffective or,
at the very least, of unknown benefit. In a systematic review,
Roughead et al.56 found that studies generally omit or in-
completely capture data on adverse drug events as a measure
of clinical outcomes of pharmacy services in the community
setting and few studies utilize medication appropriateness as
an outcome measure of pharmaceutical care.
Community Pharmacists’ Involvement in Palliative Care
Two studies that evaluated care provided by community
pharmacists to palliative care patients following training in
palliative care provide tentative support for enhancing the
role of the community pharmacist in palliative care. The first
of these studies was conducted in the United Kingdom over a
ten-month period.42 Community pharmacists developed a
therapeutic relationship with patients providing cognitive
pharmaceutical services including: assessment, medication
reviews, identifying medication-related problems, care plan-
ning, and follow-up. An expert multidisciplinary panel found
that the pharmaceutical care plans devised by community
pharmacists for twenty-five palliative care patients using local
pharmacies were likely to be beneficial. Successful outcomes
included the implementation of plans, monitoring and up-
dating of these plans, and more frequent discussion with GPs
and/or community nurses.
The second study was a 2006-2007 pilot program in San
Diego, California involving pharmacists based in a retail
ambulatory care (outpatient) setting.48 These community
pharmacists initiated or modified treatment regimens for
palliative care clinic patients under a collaborative practice
protocol and arranged follow-up appointments with the
palliative care service. Most of the pharmacists’ medication
recommendations in the SanDiego programwere accepted by
the medical professionals. Physicians in this study also re-
ported that the service was useful for managing symptoms
such as pain and nausea and that the pharmacists could spend
more time providing psychosocial support and managing
complex situations than could physicians.
Conclusion and the Way Forward
It is essential that we build upon these tentative findings
andmove forward with a coherent research agenda as robust,
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valid research is sorely lacking. We also need to support this
initiative at the systemic level by addressing structural issues
such as reimbursement and the provision of clear protocols
and policies; at the organizational level by providing guide-
lines, such as a list of essential stocks, and local resources; and
at the individual level by the provision of education and
training as well as supporting attitude changes among com-
munity pharmacists where necessary. If these initiatives are
prioritized, community pharmacists are poised to play a
valuable – and essential – role in community-based palliative
care. In summary, multilevel support for community phar-
macists is needed for pharmacists to take a greater role in
community-based palliative care. This can be achieved by
addressing barriers such as reimbursement and the lack of
education and training.
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